#China #Suzhou #WuXi XDC #BioDlink #bioconjugates

WuXi XDC and BioDlink Host 2026 Open Day: Shaping the Future Together

On June 4, 2026, WuXi XDC and BioDlink came together for their inaugural Open Day event, aptly themed "Stronger Together, Shaping the Future." This milestone marked the first event following BioDlink's strategic integration as a controlled subsidiary of WuXi XDC. It was an occasion that brought together a range of stakeholders in the biotechnology sector, including customers, industry experts, and innovators, all converging to examine how a consolidated ADC/XDC CRDMO platform can greatly enhance the development and commercialization of future bioconjugate therapies.

One of the most notable highlights was the launch ceremony, featuring key leaders from both organizations. Dr. Jimmy Li, CEO of WuXi XDC and Chairman of BioDlink, alongside Dr. Jian Zhang, Acting CEO of BioDlink, officiated the inauguration of the "Stronger Together" initiative. The event focused on establishing robust operational collaboration, which aims to deliver cohesive support from the development phase through to commercial manufacturing.

During the presentations, Dr. Jimmy Li outlined a long-term strategy for the integrated platform, emphasizing the combined expertise, global resources, and industrial capabilities that will foster significant customer value throughout the development lifecycle of bioconjugates. In his address, Dr. Jian Zhang clarified BioDlink's strategic role within the newly formed organization, shining a light on their advanced technology platforms and successful history in assisting complex ADC/XDC projects from their infancy to full-scale production.

The event also provided a valuable platform for biotechnology representatives to share insights. Dr. Junhua Qiao, CTO of GenSci, discussed effective partnership models between biotech firms and CDMO partners, basing his remarks on firsthand experiences in both sectors. Meanwhile, Dr. Yu Zhang, CMC Head of DualityBio, examined current trends in the global XDC market as well as collaborative strategies for impactful, long-term partnerships between biotech and CDMO entities, derived from his extensive experience.

A panel discussion titled "The XDC Era: Opportunities, Challenges and New Collaboration Models" was also held. Moderated by Dr. Jian Zhang, the panel comprised esteemed figures including Dr. Changjiang Huang, CSO of BioCombo Therapeutics; Dr. Zheng Wu, CEO of ArkBio; Dr. Tao Xu, CEO of SmartNuclide; and Dr. Jifeng Zhang, CTO of Lepu Biopharma. Critical industry issues were addressed, encompassing molecular complexity, challenges in Chemistry, Manufacturing, and Controls (CMC), and emerging partnership models. The consensus was clear: integrated development and manufacturing capabilities are critical in catalyzing the future of bioconjugate innovation.

Attendees also enjoyed a guided tour of BioDlink's advanced production facilities, which provided a firsthand look at their operational excellence and quality systems supporting commercial-scale output.

The 2026 Open Day served as an important landmark for both WuXi XDC and BioDlink since their integration, reinforcing their shared commitment to enhancing bioconjugate innovation. Both organizations are poised to continue expanding their integrated capabilities, empowering global innovators to provide transformative therapies to patients around the globe.

About BioDlink

BioDlink, a controlled subsidiary of WuXi XDC, is a leading global Contract Development and Manufacturing Organization (CDMO) specializing in biologics and bioconjugates, including ADCs and XDCs. With its headquarters in Suzhou and locations in Shanghai and Beijing, BioDlink offers comprehensive services from early research and development to full-scale commercial manufacturing. Their innovative platform leverages proprietary technologies such as BDKcell® for rapid cell line development and GL-DisacLink® for specific conjugation, ensuring efficiency while driving down costs.

The company operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, adhering to a global GMP-aligned quality system recognized by the PMDA in Japan, facilitating product approvals across multiple countries including China, Indonesia, Nigeria, Pakistan, Colombia, and Bolivia. Guided by the principle of "Quality First, Innovation Driven, Success Together," BioDlink is dedicated to broadening global access to next-generation biologics and nurturing trustworthy partnerships worldwide. For further information, visit biodlink.com.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code 2268.HK) is a premier global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in bioconjugates. WuXi XDC excels in providing a wide array of innovative conjugation and payload-linker technologies necessary to facilitate the development of the next generation of antibody-drug conjugates (ADCs). Committed to offering a complete range of services from preclinical research to commercial manufacturing, WuXi XDC covers antibody and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and products. More information can be found at wuxixdc.com.